KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Capital Employed (2017 - 2025)

Historic Return on Capital Employed for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 0.09%.

  • Biomarin Pharmaceutical's Return on Capital Employed rose 400.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 400.0%. This contributed to the annual value of 0.08% for FY2024, which is 400.0% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Return on Capital Employed of 0.09% as of Q3 2025, which was up 400.0% from 0.12% recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Return on Capital Employed peaked at 0.12% during Q2 2025, and registered a low of 0.02% during Q1 2021.
  • Its 5-year average for Return on Capital Employed is 0.03%, with a median of 0.03% in 2023.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -400bps in 2021, then surged by 700bps in 2025.
  • Biomarin Pharmaceutical's Return on Capital Employed (Quarter) stood at 0.02% in 2021, then soared by 286bps to 0.03% in 2022, then rose by 18bps to 0.03% in 2023, then surged by 132bps to 0.08% in 2024, then rose by 19bps to 0.09% in 2025.
  • Its last three reported values are 0.09% in Q3 2025, 0.12% for Q2 2025, and 0.1% during Q1 2025.